To do this we need to understand how this mechanism works normally, so we will test this therapeutic approach using an animal model where the pathway regulating normal
retinal blood vessel growth has been removed genetically.
Not exact matches
ROP involves an abnormal
growth of
blood vessels in the retina that may lead to scarring,
retinal detachment and, in severe cases, blindness.
In AMD, the
retinal pigment epithelial (RPE) cells that support the cells in the eye that detect light wear out, and there is also the
growth of abnormal, leaky
blood vessels below the retina.
The scientists also have demonstrated in animals that the PKal molecular pathway can induce
retinal edema through mechanisms that are independent of the VEGF pathway, which at normal levels helps to build and maintain
blood vessels but at high concentrations can induce abnormal
vessel growth and contribute to DME.
Summary: Use of eye injections of drugs aimed at slowing the
growth of abnormal
blood vessels in the eye is becoming more common for the treatment of individuals with many eye problems including macular degeneration, diabetic retinopathy and
retinal artery or vein blockage.
Dr. Chen's previous work focused on
retinal vascular biology to understand the causes and identify potential therapies to treat pathologic
blood vessel growth in eye diseases, including the wet form of AMD.
These cells protect and nourish the retina, remove waste products, prevent new
blood vessel growth into the
retinal layer, and absorb light not absorbed by the photoreceptor cells; these actions prevent the scattering of the light and enhance clarity of vision.
In
retinal diseases including age - related macular degeneration (AMD) and diabetic retinopathy, the
growth of new
blood vessels damages the retina and causes blindness.